Edgewise Therapeutics Inc (EWTX)
34.48
+0.48
(+1.41%)
USD |
NASDAQ |
Nov 04, 16:00
34.52
+0.04
(+0.12%)
Pre-Market: 08:39
Edgewise Therapeutics Cash from Investing (Quarterly): 37.37M for June 30, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 37.37M |
| March 31, 2024 | -268.31M |
| December 31, 2023 | 26.98M |
| September 30, 2023 | 23.42M |
| June 30, 2023 | 3.442M |
| March 31, 2023 | 49.04M |
| December 31, 2022 | -75.60M |
| September 30, 2022 | -26.32M |
| June 30, 2022 | -0.046M |
| Date | Value |
|---|---|
| March 31, 2022 | 31.39M |
| December 31, 2021 | 14.12M |
| September 30, 2021 | -31.61M |
| June 30, 2021 | -159.97M |
| March 31, 2021 | -64.77M |
| December 31, 2020 | -24.18M |
| September 30, 2020 | -0.006M |
| June 30, 2020 | -0.188M |
| March 31, 2020 | -0.009M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-268.31M
Minimum
Mar 2024
49.04M
Maximum
Mar 2023
-25.85M
Average
-0.0275M
Median
Cash from Investing (Quarterly) Benchmarks
| Catalyst Pharmaceuticals Inc | -0.01M |
| Vertex Pharmaceuticals Inc | -463.70M |
| Sarepta Therapeutics Inc | -98.53M |
| Regenxbio Inc | -0.268M |
| Entrada Therapeutics Inc | -24.38M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -26.10M |
| Cash from Financing (Quarterly) | 1.952M |
| Free Cash Flow | -104.72M |
| Free Cash Flow Per Share (Quarterly) | -0.2815 |
| Free Cash Flow Yield | -3.93% |